18F-Fluorodeoxyglucose PET or 18F-Fluorothymidine PET to Assess Early Response to Aromatase Inhibitors in Women With ER+ Operable Breast Cancer
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Breast Cancer Research
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
18F-fluorodeoxyglucose (FDG) PET or 18F-fluorothymidine (FLT) PET to assess early response to aromatase inhibitors (AI) in women with ER+ operable breast cancer in a window-of-opportunity study
Breast Cancer Res 2021 Aug 23;23(1)88, PE Romine, LM Peterson, BF Kurland, DW Byrd, A Novakova-Jiresova, M Muzi, JM Specht, RK Doot, JM Link, KA Krohn, PE Kinahan, DA Mankoff, HM LindenFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.